Armata Pharmaceuticals, Inc. announced that the first patient has been dosed in the company's Phase 1b/2a clinical trial ('diSArm') of AP-SA02, which is being developed for the treatment of complicated Staphylococcus aureus bacteremia. In June 2020, Armata received a $15 million award from the DoD through the Medical Technology Enterprise Consortium (MTEC) managed by the Naval Medical Research Center with funding from the Defense Health Agency and Joint Warfighter Medical Research Program, to evaluate safety and tolerability of AP-SA02 as an adjunct to best available antibiotic therapy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.59 USD | -2.26% | -16.21% | -20.06% |
May. 07 | Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000 | MT |
Mar. 21 | Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.06% | 93.64M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- ARMP Stock
- News Armata Pharmaceuticals, Inc.
- Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus Aureus